A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder, in different regions of the airways in prophylaxis/ treatment/ diagnosis of pulmonary and systemic disorders [1]. Interest in DPI as an efficient and environmentally friendly way of delivering drugs to the lung has accelerated in recent years [2]. Most of the Pharmaceutical companies are now prioritizing in the development of dry powder inhalers (DPIs) above pressurized formulations for the delivery of medications to treat various lungs diseases [3]. The efficacy of the drug and its treatment can be achieved from the new ideas on controlling the pharmacokinetics, pharmacodynamics, formulation, an efficient metering system, and a carefully selected device [4]. This study provides an in-depth analysis of the development in the methods to identify lung deposition study and in-vitro evaluation of dry powder inhalers.
Impact Factor
2022: 6.012
This work is licensed under a